A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs ICT 107 (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms STING
- Sponsors ImmunoCellular Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 15 May 2017 According to an ImmunoCellular Therapeutics media release, due to limited financial resources company's board of directors are determining the strategy to continue this trial either independently, in partnership or by acquisition of the asset.
- 15 May 2017 According to an ImmunoCellular Therapeutics media release, the Company increased the number of sites participating in this trial during the quarter ended March 31, 2017.